Skip to main content

2010 New Drug Approvals - Pt. XV - Lurasidone (Latuda)



ATC code (partial): N05AE


On October 28th 2010, the FDA approved Lurasidone (Tradename:Latuda) (Lurasidone is also known by the research code SM-13,496). Lurasidone is an atypical antipsychotic agent indicated for the treatment schizophrenia.

Lurasidone displays broad polypharmacology against a wide range of rhodopsin-like aminergic GPCRs, acting as an antagonist with high affinity at dopamine D2 receptors (Uniprot: P14416, ChEMBL: 72) (Ki of 1 nM), serotonin 5-HT2A (Uniprot: P28223, ChEMBL: 107) (Ki of 0.47 nM) and 5-HT7 receptors (Uniprot: P34969, ChEMBL: 10209) (Ki of 0.49 nM), and with moderate affinity at alpha-2C adrenergic receptors (Uniprot: P18825, ChEMBL: 218) (Ki of 10.8 nM) and at alpha-2A adrenergic receptors (Uniprot: P08913, ChEMBL: 52) (Ki of 40.7 nM). Lurasidone acts also as a partial agonist at serotonin 5-HT1A receptors (Uniprot: P08908, ChEMBL: 51) (Ki of 6.4 nM) and exhibits little or no affinity for histamine H1 (Uniprot: P35367, ChEMBL: 127) and muscarinic M1 receptors (Uniprot: P11229, ChEMBL: 61) (IC50 > 1000 nM and IC50 > 1000 nM, respectively). The efficacy of Luasidone is thought to be primarily related to the D2 and 5HT2A antagonism. All atypical antipsychotics display this complex polypharmacology.

Lurasidone is a synthetic small-molecule drug (Molecular Weight of 492.7 g/mol for Lurasidone itself and 529.14 g.mol-1 for the dosed HCl salt), is fully Rule-of-Five compliant, lipophilic and very slightly soluble in water.

Lurasidone has low systemic bioavailability (9-19%), and a high volume of distribution of 6173L, and displays high plasma protein binding (ppb) of ~99%. The half life is 18 hours, and steady-state plasma levels are reached 7 days after starting regular dosing. Lurasidone is predominantly metabolized by CYP3A4 into four major metabolites (two active metabolites and two 'inactive') - metabolites include hydroxylation of the nornbornane ring, N-dealkylation and S-oxidation. The apparent clearance is 3902mL/min, with the bulk of the drug being excreted in the feces. Dosage is oral, with a recommended starting dosage is 40 mg once daily (equivalent to 81umol), with a recommended maximum dosage of 80 mg daily.


Lurasidone is a chiral benzoisothiazol derivative - the benzoisothiazol is the fused five-six dual ring structure on the right of the figure above. Its structure (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione contains an imide heterocyclic and a piperazine functional group. The central piperazine nitrogen is basic. The chemical structure, properties and pharmacology are similar to Ziprasidone (Trademark:Geodon).

NAME="Lurasidone"
TRADEMARK_NAME="Latuda"
ATC_code= NA
SMILES="O=C1C2[C@@H]3CC[C@@H](C3)C2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)c6nsc7ccccc67"
InChI="InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24?,25?/m0/s1"
ChemDraw=Lurasidone.cdx

The full prescribing information can be found here.

Lurasidone has a boxed warning (colloquially known as a 'black box').

The license holder is Sunovion Pharmaceuticals Inc. and the product website is www.latuda.com

Comments

Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the